Table of contents

Rheumatoid arthritis

• Viewpoint: On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis (28 September, 2024)

  Olivier Vittecoq, Pauline Brevet, Baptiste Gerard, Thierry Lequerre
• Original research: Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials (5 September, 2024)

  Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Kaja E Kjørholt, Lena Bugge Nordberg, Ellen Moholt, Till Uhlig, Désirée van der Heijde, Daniel H Solomon, Espen A Haavardsholm, Siri Lillegraven, Anna-Birgitte Aga
• Original research: Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis (22 August, 2024)

  Yoshiya Tanaka, Yusuke Miyazaki, Masafumi Kawanishi, Hironori Yamasaki, Tsutomu Takeuchi
• Original research: Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial (7 August, 2024)

  Delphine Bertrand, Johan Joly, Barbara Neerinckx, Patrick Durez, Jan Lenaerts, Rik Joos, Kristof Thevissen, Tom Zwaenepoel, Johan Vanhoof, Silvana Di Romana, Veerle Taelman, Els Van Essche, Luk Corluy, Clio Ribbens, Marc Vanden Berghe, Mieke Devinck, Sofia Ajeganova, Anne Durnez, Yves Boutsen, Joëlle Margaux, Isabelle Peene, Jan Van Offel, Michaël Doumen, Sofia Pazmino, Elias De Meyst, Myroslava Kulyk, Nelly Creten, René Westhovens, Patrick Verschueren
• Original research: Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study (25 July, 2024)

  Roy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
• Original research: Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND (24 July, 2024)

  Ronald F van Vollenhoven, Stephen Hall, Alvin F Wells, Sebastian Meerwein, Yanna Song, Oishi Tanjinatus, Roy Fleischmann
• Original research: Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis (23 July, 2024)

  George Athanasios Karpouzas, Sarah R Ormseth, Piet Leonardus Cornelis Maria van Riel, Miguel A Gonzalez-Gay, Alfonso Corrales, Solbritt Rantapää-Dahlqvist, Petros P Sfikakis, Patrick Dessein, Linda Tsang, Carol Hitchon, Hani El-Gabalawy, Virginia Pascual-Ramos, Irazú Contreras-Yáñez, Iris J Colunga-Pedraza, Dionicio Angel Galarza-Delgado, Jose Ramon Azpiri-Lopez, Anne Grete Semb, Durga Prasanna Misra, Ellen-Margrethe Hauge, George Kitas
• Original research: Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response (22 July, 2024)

  Mikhail Volkov, Arieke S B Kampstra, Karin A J van Schie, Anouk G van Mourik, Joanneke C Kwekkeboom, Arnoud de Ru, Peter A van Veelen, Tom W J Huizinga, René E M Toes, Diane van der Woude
• Letter: Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis? (20 July, 2024)

  Judith W Heutz, Agnes E M Looijen, Annette H M van der Helm-van Mil, Pascal H P de Jong, Elise van Mulligen
• Original research: What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis audit (14 July, 2024)

  Maryam Adas, Mrinalini Dey, Sam Norton, Heidi Lempp, Maya H Buch, Andrew Cope, James Galloway, Elena Nikiphorou